Clinical trials
Active, not recruiting Myelodysplastic Syndromes trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
95 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 2 |
| 2008 | 1 |
| 2009 | 3 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 4 |
| 2016 | 5 |
| 2017 | 5 |
| 2018 | 4 |
| 2019 | 11 |
| 2020 | 13 |
| 2021 | 12 |
| 2022 | 11 |
| 2023 | 14 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Active, not recruiting | 95 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| City of Hope Medical Center | 10 |
| M.D. Anderson Cancer Center | 10 |
| National Cancer Institute (NCI) | 9 |
| St. Jude Children's Research Hospital | 4 |
| Baylor College of Medicine | 3 |
| Bellicum Pharmaceuticals | 3 |
| Bristol-Myers Squibb | 3 |
| Massachusetts General Hospital | 3 |
| Memorial Sloan Kettering Cancer Center | 3 |
| Novartis Pharmaceuticals | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Myelodysplastic Syndromes | 95 |
| Leukemia, Myeloid, Acute | 56 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 27 |
| Leukemia, Myelomonocytic, Chronic | 25 |
| Myeloproliferative Disorders | 21 |
| Lymphoma, Non-Hodgkin | 16 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 14 |
| Leukemia | 12 |
| Hematologic Neoplasms | 10 |
| Hodgkin Disease | 10 |
Trials
Showing 1 to 25 of 95. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.